Not finding it? Sign in to also search OpenAlex live.
-
A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy2024 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Yuka Sugimoto, Eran Zimran, Yoshimitsu Shimomura, Hiroki Yamaguchi, Hans Carl Hasselbach, Jean‐Jacques Kiladjian, +14 more
2citations -
Shorespan-007: Phase 3 study of bomedemstat versus hydroxyurea in essential thrombocythemia naive to cytoreductive therapy.2025 Journal of Clinical Oncology conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Kristen Marie Pettit, Yuka Sugimoto, Eran Zimran, Yoshimitsu Shimomura, Hiroki Yamaguchi, Hans Carl Hasselbach, +14 more
0citations -
Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis
Judith S. E. Quik, Marieke A. Vollebergh, Valesca P. Retèl, Karen van der Sluis, Willem J. Koemans, Rosa T. van der Kaaij, +18 more
5citations -
Mitigation of atrial fibrillation‐related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG‐MPN bioregistry
Hyunyee Rosa Cho, Susanne Isfort, Kim Kricheldorf, Frank Stegelmann, Martine Klausmann, Florian Heinrich Heidel, +14 more
0citations -
MPN-985: Effect of Rusfertide on Cytoreductive Therapy Use in Patients With Phlebotomy-Dependent Polycythemia Vera: Post Hoc Analysis From the Randomized Controlled Phase 3 VERIFY Study2026 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment
Andrew T Kuykendall, Francesca Palandri, Gregory Sumpao Vosganian, Aniket Bankar, Naveen Pemmaraju, Kristen Marie Pettit, +18 more
0citations -
POSTER: MPN-985: Effect of Rusfertide on Cytoreductive Therapy Use in Patients With Phlebotomy-Dependent Polycythemia Vera: Post Hoc Analysis From the Randomized Controlled Phase 3 VERIFY Study2026 Clinical Lymphoma Myeloma & Leukemia article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment
Andrew T Kuykendall, Francesca Palandri, Gregory Sumpao Vosganian, Aniket Bankar, Naveen Pemmaraju, Kristen Marie Pettit, +18 more
0citations -
Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Andrew Tucker Kuykendall, Aniket Bankar, Kristen Marie Pettit, Joseph James Shatzel, Alessandro Lucchesi, Valentín García‐Gutiérrez, +20 more
3citations -
Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR2021 Annals of Surgery article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Stéphanie A. Blankenstein, Maartje W. Rohaan, W. Martin C. Klop, Bernies van der Hiel, Bart A. van de Wiel, Max J. Lahaye, +11 more
48citations -
ASO Visual Abstract: The Role of Adjuvant Use of the PlasmaJet® Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer—Results of the PlaComOv-Study, a Randomized, Controlled Trial in the Netherlands2022 Annals of Surgical Oncology article Medicine Ovarian cancer diagnosis and treatment Open access
Gatske M. Nieuwenhuyzen-de Boer, W. Hofhuis, N. Reesink-Peters, Sten Willemsen, I. A. Boere, Ivo G. Schoots, +12 more
0citations -
Exploiting the synergistic effect of PARP inhibition with cisplatin and hyperthermia during interval cytoreductive surgery and HIPEC in ovarian cancer: the PROOV study - A phase I/II clinical trial2026 International Journal of Gynecological Cancer article Medicine Intraperitoneal and Appendiceal Malignancies
Leah Frenkel, Madelief Schreuder Goedheijt, Carolina Velázquez, Marta López‐Yurda, Daniela Annibali, Frans L. Opdam, +7 more
0citations -
Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study
Steffen Koschmieder, Eyck von der Heyde, Lambert Busque, Françoise Boyer‐Perrard, Timothy Devos, Francesco Passamonti, +9 more
1citations -
Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
Steffen Koschmieder, Susanne Isfort, Lino Lars Teichmann, Philippe Schafhausen, Florian Heinrich Heidel, Andreas Hochhaus, +18 more
4citations -
Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT2026 Bone Marrow Transplantation article Medicine Multiple Myeloma Research and Treatments Open access
Nico Gagelmann, Maximilian Merz, Laurien G.A. Baaij, Linda Köster, Jorinde Desiree Hoogenboom, Joanna Ewa Drozd-Sokolowska, +7 more
1citations -
Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
Steffen Koschmieder, Susanne Isfort, Florian Heinrich Heidel, Andreas Hochhaus, Heiko Becker, Philipp Jakob Jost, +19 more
3citations -
Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study2025 Therapeutic Advances in Hematology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Steffen Koschmieder, Eyck von der Heyde, Lambert Busque, Françoise Boyer‐Perrard, Timothy Devos, Francesco Passamonti, +5 more
1citations -
Ex vivo 3D micro-tumor testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer.2025 Journal of Clinical Oncology conference-abstract Medicine Ovarian cancer diagnosis and treatment Open access
Cor Doede de Kroon, Judith R. Kroep, Petronella Beatrix Ottevanger, Anne M. van Altena, Els L. van Persijn-van Meerten, L. Ceton, +4 more
0citations -
Long-term Outcome of a DLI-based Treatment Strategy in Patients With Relapsed AML After TCD Allogeneic Stem Cell Transplantation is Hampered by GvHD and Late Relapse2026 Transplantation and Cellular Therapy article Medicine Hematopoietic Stem Cell Transplantation Open access
J.E. Bergsma, Eva M. Argiro, K A Oosterink, Peter van Balen, J.G.K. van der Hem, Daniëlle van Lammeren, +6 more
1citations -
ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options
Jean‐Jacques Kiladjian, Francisca Ferrer‐Marín, Haifa Kathrin Al‐Ali, Alberto Álvarez‐Larrán, Eloise Beggiato, Maria Bieniaszewska, +35 more
0citations